Amiotrófiás laterálszklerózis (ALS): vizsgálatok itt: Svédország
8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 14.. Ask the study team whether a trial fits you.
- 3. fázisTaking peoplePridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
- Where
- Stockholm, Umeå
- Életkor
- 18 év to 80 év
- People
- 500 worldwide
- Run by
- Prilenia
See details and how to joinNCT07322003 - 1/2. fázisTaking peopleFirst in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
- Where
- Huddinge, Umeå
- Életkor
- 18 év and over
- People
- 54 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06351592 · EU 2023-510344-20-00 - 2. fázisTaking peopleUsnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
- Where
- Malmo, Stockholm, Umea
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Zydus Therapeutics Inc.
See details and how to joinNCT07023835 · EU 2025-522580-15-00 - 1/2. fázisTaking peopleA Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis
- Where
- Huddinge, Umea
- Életkor
- 18 év to 75 év
- People
- 56 worldwide
- Run by
- Leal Therapeutics, Inc
See details and how to joinNCT07660614 · EU 2025-522039-33-00 - 3. fázisTaking peoplePridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS)
- Where
- Stockholm, Umea
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- Ferrer Internacional S.A.
See details and how to join2025-524002-16-00 - 2. fázisTaking peopleThe Swedish BioFINDER 2 Study
- Where
- Malmö
- Életkor
- 20 év to 100 év
- People
- 2950
- Run by
- Skane University Hospital
See details and how to joinNCT03174938 · EU 2024-511842-38-00 - 3. fázisVisszavonvaEfficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients
- Where
- Umeå
- Életkor
- 18 év to 80 év
- People
- 412 worldwide
- Run by
- AB Science
See details and how to joinNCT07174492 · EU 2024-511244-12-01 - 3. fázisTaking peopleEfficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
- Where
- Karlstad, Malmö, Umeå
- Életkor
- 18 év to 81 év
- People
- 495 worldwide
- Run by
- AB Science
See details and how to joinNCT03127267